Alamar Biosciences Expands NULISAseq™ CNS Disease Panel with Advanced Blood Tests

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel



Alamar Biosciences, a leading company in precision proteomics, has made a significant advancement in the detection of neurodegenerative diseases by expanding its NULISAseq™ CNS Disease Panel 120. This enhancement introduces groundbreaking assays for phosphorylated tau (pTau) proteins that are derived specifically from the brain, allowing for early detection and better monitoring of conditions such as Alzheimer's disease.

On May 15, 2025, the company announced that the NULISAseq™ CNS Disease Panel now includes new assays for pTau217, pTau181, pTau231, and total tau (tTau), all of which can be measured directly in blood samples. This innovative approach aims to enhance the sensitivity and specificity of testing for neurodegenerative diseases, which is crucial for effective research and patient outcomes.

The Importance of pTau Biomarkers



Phosphorylated tau has emerged as a critical biomarker in the early detection and progression tracking of Alzheimer's disease and related tauopathies. Previous tests have struggled to distinguish between peripheral and central nervous system tau sources. The newly enhanced panel tackles these limitations, allowing simultaneous measurement of various pTau species specifically from the brain while also providing data that combines both brain-derived and peripheral-derived tau species.

Dr. Yuling Luo, CEO and Founder of Alamar Biosciences, emphasized the significance of this development: "Researchers have long been seeking a reliable blood-based solution for tracking brain-derived tau pathology. By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq™ CNS Disease Panel 120, we enable scientists to investigate the entire spectrum of tau pathology with outstanding sensitivity and performance. This leap will accelerate biomarker-based research and drug development for Alzheimer's and related neurodegenerative disorders."

Enhancing Diagnostic Specificity



Dr. Nicholas Ashton, Director of Neurodegenerative Biomarkers Research at Banner Health, acknowledged the panel's potential to revolutionize early detection and monitoring of Alzheimer's disease. He stated, "Until now, we have been unable to multiplex brain-derived and peripheral pTaus effectively. Recent evidence highlights the need to detect brain-specific pTau for greater diagnostic specificity in Alzheimer's disease. The new CNS panel from Alamar offers an unprecedented opportunity to enhance the diagnostic accuracy and clinical utility of these biomarkers, significantly impacting patient care and clinical research."

Alamar Biosciences remains committed to collaborating with the neuroscience community, actively seeking insights into biomarkers that will foster early diagnosis, patient stratification, and therapy monitoring. By providing advanced tools for research, Alamar aims to contribute to a deeper understanding of neurodegenerative diseases and improve outcomes for patients.

For more information about the NULISAseq™ CNS Disease Panel 120 and Alamar’s range of proteomic solutions, visit www.alamarbio.com.

About Alamar Biosciences, Inc.



Founded with the mission to advance precision proteomics for early disease detection, Alamar Biosciences operates in the life sciences sector. Their proprietary NULISA platform and ARGO™ HT system seamlessly integrate state-of-the-art genomic advancements to achieve ultra-sensitive detection capabilities, far surpassing existing protein detection technologies on the market today. For further information, visit alamarbio.com.

Alamar Logo

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.